본문 바로가기
KERD
논문KCI 등재

Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update

Fukui Hiroshi
거트앤리버 소화기연관학회협의회|2021.09|Gut and Liver|제15권 제5호|pp. 666-676|DOI 10.5009/gnl20032

0

조회

0

다운로드

3

인용

0

참고문헌

키워드

Liver cirrhosisEndotoxinGut-liver axisGut dysbiosisGut dysmotility

초록

Portal blood flows into the liver containing the gut microbiome and its products such as endotoxin and bacterial DNA. The cirrhotic liver acts and detoxifies as the initial site of microbial products. In so-called “leaky gut,” the increased intestinal permeability for bacteria and their products constitutes an important pathogenetic factor for major complications in patients with liver cirrhosis. Prolonged gastric and small intestinal transit may induce intestinal bacterial overgrowth, a condition in which colonic bacteria translocate into the small gut. Cirrhotic patients further show gut dysbiosis characterized by an overgrowth of potentially pathogenic bacteria and a decrease in autochthonous nonpathogenic bacteria. Pathological bacterial translocation (BT) is a contributing factor in the development of various severe complications. Bile acids (BAs) undergo extensive enterohepatic circulation and play important roles in the gut-liver axis. BT-induced inflammation prevents synthesis of BAs in the liver through inhibition of BA-synthesizing enzyme CYP7A1. A lower abundance of 7α-dehydroxylating gut bacteria leads to decreased conversion of primary to secondary BAs. Decreases in total and secondary BAs may play an important role in the gut dysbiosis characterized by a proinflammatory and toxic gut microbiome inducing BT and endotoxemia, as addressed in my previous reviews. Selective intestinal decontamination by the use of various antimicrobial drugs for management of complications has a long history. Lactobacillus GG decreasing endotoxemia is reported to improve the microbiome with beneficial changes in amino acid, vitamin and secondary BA metabolism. Current approaches for hepatic encephalopathy are the use of nonabsorbable antibiotics and disaccharides. Probiotics may become an additional therapeutic option for advanced liver cirrhosis.

Abstract

Portal blood flows into the liver containing the gut microbiome and its products such as endotoxin and bacterial DNA. The cirrhotic liver acts and detoxifies as the initial site of microbial products. In so-called “leaky gut,” the increased intestinal permeability for bacteria and their products constitutes an important pathogenetic factor for major complications in patients with liver cirrhosis. Prolonged gastric and small intestinal transit may induce intestinal bacterial overgrowth, a condition in which colonic bacteria translocate into the small gut. Cirrhotic patients further show gut dysbiosis characterized by an overgrowth of potentially pathogenic bacteria and a decrease in autochthonous nonpathogenic bacteria. Pathological bacterial translocation (BT) is a contributing factor in the development of various severe complications. Bile acids (BAs) undergo extensive enterohepatic circulation and play important roles in the gut-liver axis. BT-induced inflammation prevents synthesis of BAs in the liver through inhibition of BA-synthesizing enzyme CYP7A1. A lower abundance of 7α-dehydroxylating gut bacteria leads to decreased conversion of primary to secondary BAs. Decreases in total and secondary BAs may play an important role in the gut dysbiosis characterized by a proinflammatory and toxic gut microbiome inducing BT and endotoxemia, as addressed in my previous reviews. Selective intestinal decontamination by the use of various antimicrobial drugs for management of complications has a long history. Lactobacillus GG decreasing endotoxemia is reported to improve the microbiome with beneficial changes in amino acid, vitamin and secondary BA metabolism. Current approaches for hepatic encephalopathy are the use of nonabsorbable antibiotics and disaccharides. Probiotics may become an additional therapeutic option for advanced liver cirrhosis.

참고문헌 (97)

  1. Pinzani M, "Liver cirrhosis", Best Pract Res Clin Gastroenterol, 25, pp.281~290 (2011)
  2. Tandon P, "Bacterial infections, sepsis, and multiorgan failure in cirrhosis", Semin Liver Dis, 28, pp.26~42 (2008)
  3. Arvaniti V, "Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis", Gastroenterology, 139, pp.1246~1256 (2010)
  4. Pinzone MR, "Microbial translocation in chronic liver diseases", Int J Microbiol, 2012, pp.694629~ (2012)
  5. Bellot P, "Pathological bacterial translocation in cirrhosis : pathophysiology, diagnosis and clinical implications", Liver Int, 33, pp.31~39 (2013)
  6. Fukui H, "Role of gut dysbiosis in liver diseases: what have we learned so far?", Diseases, 7, pp.58~ (2019)
  7. Seo YS, "The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension", Clin Mol Hepatol, 18, pp.337~346 (2012)
  8. Guo J, "Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis", Fibrogenesis Tissue Repair, 3, pp.21~ (2010)
  9. Seki E, "Role of innate immunity and the microbiota in liver fibrosis : crosstalk between the liver and gut", J Physiol, 590, pp.447~458 (2012)
  10. Fukui H, "Gut-liver axis in liver cirrhosis : how to manage leaky gut and endotoxemia", World J Hepatol, 7, pp.425~442 (2015)
  11. Prytz H, "Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis", Scand J Gastroenterol, 11, pp.857~863 (1976)
  12. Fukui H, "Gut and the liver", pp.251~262 (1998), Kluwer Academic Publishers
  13. Lin RS, "Endotoxemia in patients with chronic liver diseases : relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation", J Hepatol, 22, pp.165~172 (1995)
  14. Fujimoto M, "Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis : relation to severity of liver disturbance", Alcohol Clin Exp Res, 24(4 Suppl), pp.48S~54S (2000)
  15. Fukui H, "Gut microbiome-based therapeutics in liver cirrhosis : basic consideration for the next step", J Clin Transl Hepatol, 5, pp.249~260 (2017)
  16. Topping DL, "Short-chain fatty acids and human colonic function : roles of resistant starch and nonstarch polysaccharides", Physiol Rev, 81, pp.1031~1064 (2001)
  17. Leung C, "The role of the gut microbiota in NAFLD", Nat Rev Gastroenterol Hepatol, 13, pp.412~425 (2016)
  18. Shen TD, "Microbiota and the liver", Liver Transpl, 24, pp.539~550 (2018)
  19. Schwiertz A, "Microbiota and SCFA in lean and overweight healthy subjects", Obesity(Silver Spring), 18, pp.190~195 (2010)
  20. Willemsen LE, "Short chain fatty acids stimulate epithelial mucin 2expression through differential effects on prostaglandin E(1)and E(2)production by intestinal myofibroblasts", Gut, 52, pp.1442~1447 (2003)
  21. Ohira H, "Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis?", J Atheroscler Thromb, 24, pp.660~672 (2017)
  22. Ridlon JM, "Bile salt biotransformations by human intestinal bacteria", J Lipid Res, 47, pp.241~259 (2006)
  23. Ridlon JM, "Cirrhosis, bile acids and gut microbiota : unraveling a complex relationship", Gut Microbes, 4, pp.382~387 (2013)
  24. Wang H, "Endogenous bile acids are ligands for the nuclear receptor FXR", BAR, 1999, pp.3, 543~553
  25. Maruyama T, "Identification of membrane-type receptor for bile acids(M-BAR)", Biochem Biophys Res Commun, 298, pp.714~719 (2002)
  26. Keitel V, "Perspective : TGR5(Gpbar-1)in liver physiology and disease", Clin Res Hepatol Gastroenterol, 36, pp.412~419 (2012)
  27. Matsubara T, "FXR signaling in the enterohepatic system", Mol Cell Endocrinol, 368, pp.17~29 (2013)
  28. Pijls KE, "Intestinal epithelial barrier function in liver cirrhosis : an extensive review of the literature", Liver Int, 33, pp.1457~1469 (2013)
  29. Stanimirov B, "Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases", Hepatobiliary Pancreat Dis Int, 14, pp.18~33 (2015)
  30. Ridlon JM, "Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut", Dig Dis, 33, pp.338~345 (2015)
  31. Hofmann AF, "How bile acids confer gut mucosal protection against bacteria", Proc Natl Acad Sci U S A, 103, pp.4333~4334 (2006)
  32. Parks RW, "Intestinal barrier dysfunction in clinical and experimental obstructive jaundice and its reversal by internal biliary drainage", Br J Surg, 83, pp.1345~1349 (1996)
  33. Reynolds JV, "Gut barrier failure in experimental obstructive jaundice", J Surg Res, 62, pp.11~16 (1996)
  34. Inagaki T, "Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor", Proc Natl Acad Sci U S A, 103, pp.3920~3925 (2006)
  35. Gadaleta RM, "Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease", Gut, 60, pp.463~472 (2011)
  36. Úbeda M, "Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats", J Hepatol, 64, pp.1049~1057 (2016)
  37. Verbeke L, "The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats", Am J Pathol, 185, pp.409~419 (2015)
  38. Verbeke L, "Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats", Hepatology, 59, pp.2286~2298 (2014)
  39. Fukui H, "Gut microbiota and host reaction in liver diseases", Microorganisms, 3, pp.759~791 (2015)
  40. Bajaj JS, "Altered profile of human gut microbiome is associated with cirrhosis and its complications", J Hepatol, 60, pp.940~947 (2014)
  41. Madrid AM, "Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease", Dig Dis Sci, 42, pp.738~742 (1997)
  42. Van Thiel DH, "Gastrointestinal transit in cirrhotic patients : effect of hepatic encephalopathy and its treatment", Hepatology, 19, pp.67~71 (1994)
  43. Galati JS, "Gastric emptying and orocecal transit in portal hypertension and end-stage chronic liver disease", Liver Transpl Surg, 3, pp.34~38 (1997)
  44. Kalaitzakis E, "Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis", Clin Gastroenterol Hepatol, 7, pp.346~352 (2009)
  45. Chander Roland B, "Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls", J Clin Gastroenterol, 47, pp.888~893 (2013)
  46. Chen CY, "Delayed gastrointestinal transit in patients with hepatocellular carcinoma", J Gastroenterol Hepatol, 17, pp.1254~1259 (2002)
  47. Chang CS, "Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis", Hepatology, 28, pp.1187~1190 (1998)
  48. Nagasako CK, "Investigation of autonomic function and orocecal transit time in patients with nonalcoholic cirrhosis and the potential influence of these factors on disease outcome", J Clin Gastroenterol, 43, pp.884~889 (2009)
  49. Thalheimer U, "Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis : a pilot study", Eur J Gastroenterol Hepatol, 22, pp.1228~1234 (2010)
  50. Chacko A, "Colonic function in cirrhosis of liver & in healthy controls", Indian J Med Res, 105, pp.220~225 (1997)
  51. Palma P, "Intestinal barrier dysfunction in developing liver cirrhosis : an in vivo analysis of bacterial translocation", Hepatol Res, 37, pp.6~12 (2007)
  52. Artis D, "Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut", Nat Rev Immunol, 8, pp.411~420 (2008)
  53. Bäckhed F, "Host-bacterial mutualism in the human intestine", Science, 307, pp.1915~1920 (2005)
  54. McCormack TT, "Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy?", Gut, 26, pp.1226~1232 (1985)
  55. Chen LS, "Portal hypertensive colopathy in patients with cirrhosis", Scand J Gastroenterol, 31, pp.490~494 (1996)
  56. Pienkowski P, "Functional study, in man, of congestive gastropathy in cirrhosis by measurement of potential difference", Gastroenterol Clin Biol, 13, pp.763~768 (1989)
  57. Guslandi M, "Breakdown of mucosal defences in congestive gastropathy in cirrhotics", Liver, 12, pp.303~305 (1992)
  58. Guslandi M, "Assessment of mucosal defenses in portal hypertensive gastropathy", J Hepatol, 16, pp.248~ (1992)
  59. Fukui H, "Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation?", Inflamm Intest Dis, 1, pp.135~145 (2016)
  60. Barakat M, "Portal hypertensive duodenopathy : clinical, endoscopic, and histopathologic profiles", Am J Gastroenterol, 102, pp.2793~2802 (2007)
  61. Misra V, "Histomorphometric study of portal hypertensive enteropathy", Am J Clin Pathol, 108, pp.652~657 (1997)
  62. Bhonchal S, "Functional and morphological alterations in small intestine mucosa of chronic alcoholics", J Gastroenterol Hepatol, 23(7 Pt 2), pp.e43~e48 (2008)
  63. De Palma GD, "Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension : a capsule endoscopy study", Gastrointest Endosc, 62, pp.529~534 (2005)
  64. Canlas KR, "Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia", J Clin Gastroenterol, 42, pp.844~848 (2008)
  65. Korthuis RJ, "Intestinal capillary filtration in experimental diabetes mellitus", Am J Physiol, 253(1 Pt 1), pp.G20~G25 (1987)
  66. Kalaitzakis E, "Gastrointestinal dysfunction in liver cirrhosis", World J Gastroenterol, 20, pp.14686~14695 (2014)
  67. Scarpellini E, "Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?", Am J Gastroenterol, 105, pp.323~327 (2010)
  68. Campillo B, "Intestinal permeability in liver cirrhosis : relationship with severe septic complications", Eur J Gastroenterol Hepatol, 11, pp.755~759 (1999)
  69. Kalaitzakis E, "Intestinal permeability in cirrhotic patients with and without ascites", Scand J Gastroenterol, 41, pp.326~330 (2006)
  70. Ersöz G, "Intestinal permeability in liver cirrhosis", Eur J Gastroenterol Hepatol, 11, pp.409~412 (1999)
  71. Huglo D, "Simultaneous determination of pulmonary and intestinal permeability in patients with alcoholic liver cirrhosis", Eur J Nucl Med, 28, pp.1505~1511 (2001)
  72. Zuckerman MJ, "Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes", Dig Dis Sci, 49, pp.621~626 (2004)
  73. Wang L, "Methods to determine intestinal permeability and bacterial translocation during liver disease", J Immunol Methods, 421, pp.44~53 (2015)
  74. Pascual S, "Intestinal permeability is increased in patients with advanced cirrhosis", Hepatogastroenterology, 50, pp.1482~1486 (2003)
  75. Dastych M, "Lactulose", mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn’s disease, 2008, pp.53, 2789~2792
  76. Perera L, "Expression of nonclassical class I molecules by intestinal epithelial cells", Inflamm Bowel Dis, 13, pp.298~307 (2007)
  77. DeMeo MT, "Intestinal permeation and gastrointestinal disease", J Clin Gastroenterol, 34, pp.385~396 (2002)
  78. Hossain MI, "Intestinal mucosal permeability of severely underweight and nonmalnourished Bangladeshi children and effects of nutritional rehabilitation", J Pediatr Gastroenterol Nutr, 51, pp.638~644 (2010)
  79. Bjarnason I, "Intestinal permeability", Gut, 35(1Suppl), pp.S18~S22 (1994)
  80. Bjarnason I, "Intestinal permeability : an overview", Gastroenterology, 108, pp.1566~1581 (1995)
  81. Keshavarzian A, "Leaky gut in alcoholic cirrhosis : a possible mechanism for alcohol-induced liver damage", Am J Gastroenterol, 94, pp.200~207 (1999)
  82. Pijls KE, "Large intestine permeability is increased in patients with compensated liver cirrhosis", Am J Physiol Gastrointest Liver Physiol, 306, pp.G147~ (2014)
  83. Parlesak A, "Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease", J Hepatol, 32, pp.742~747 (2000)
  84. Lee S, "Increased intestinal macromolecular permeability and urine nitrite excretion associated with liver cirrhosis with ascites", World J Gastroenterol, 14, pp.3884~3890 (2008)
  85. Kim BI, "Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage", J Gastroenterol Hepatol, 26, pp.550~557 (2011)
  86. Othman M, "Alterations in intestinal mi-crobial flora and human disease", Curr Opin Gastroenterol, 24, pp.11~16 (2008)
  87. Sekirov I, "Gut microbiota in health and disease", Physiol Rev, 90, pp.859~904 (2010)
  88. Gupta A, "Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy", J Hepatol, 53, pp.849~855 (2010)
  89. Bauer TM, "Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia", Am J Gastroenterol, 97, pp.2364~2370 (2002)
  90. Casafont Morencos F, "Small bowel bacterial overgrowth in patients with alcoholic cirrhosis", Dig Dis Sci, 41, pp.552~556 (1996)
  91. Wiest R, "Targeting the gut-liver axis in liver disease", J Hepatol, 67, pp.1084~1103 (2017)
  92. Gómez-Hurtado I, "Gut microbiota-related complications in cirrhosis", World J Gastroenterol, 20, pp.15624~15631 (2014)
  93. Chen Y, "Characterization of fecal microbial communities in patients with liver cirrhosis", Hepatology, 54, pp.562~572 (2011)
  94. Bajaj JS, "Linkage of gut microbiome with cognition in hepatic encephalopathy", Am J Physiol Gastrointest Liver Physiol, 302, pp.G168~ (2012)
  95. Liu H, "Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC", RID, Bioorg Med Chem Lett, pp.2004, 14[DOI]
  96. Qin N, "Alterations of the human gut microbiome in liver cirrhosis", Nature, 513, pp.59~64 (2014)
  97. Bajaj JS, "Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation", Am J Physiol Gastrointest Liver Physiol, 303, pp.G675~ (2012)[DOI]

관련 논문AI추천

Gut microbiome and metabolome signatures in liver cirrhosis-related complications양동훈, Dong Joon Kim, Goo-Hyun Kwon, Gwang Ho Baik, Haripriya Gupta, Hyunjoon Park, Jeong Ha Park, Jeoung Su Kim, Jin-Ju Jeong, Jung A Eom, Ki-Kwang Oh, Ki Tae Suk, Kyeong Jin Lee, Min Ju Kim, Sang Jun Yoon, Sang Yoon Lee, Satya Priya Sharma, Seol Hee Song, Sung-Min Won, Young Lim Ham대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Changes in the epidemiology and management of bacterial infections in cirrhosisMarta Tonon, Paolo Angeli, Salvatore Piano대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제3호Microbiota, a key player in alcoholic liver diseaseAnne-Marie Cassard, Dragos Ciocan대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제2호Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction- Associated Steatotic Liver DiseaseChao Cui, Jingfei Shi, Kai Wang, Shuai Gao거트앤리버 소화기연관학회협의회 · Gut and Liver2025 · 제19권 제4호Host-Microbiome Interactions in Alcoholic Liver DiseaseBernd Schnabl, Peng Chen거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제3호The Role of Intestinal Fungi and Its Metabolites in Chronic Liver DiseasesJingxin Zhou, Junping Shi, Lili Zhuo, Ningning You, Yu Song거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제3호

이 간행물의 다른 논문 (17건)

Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease김은수pp. 637-638Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?김은수, Lee Jin Wookpp. 639-640Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?천재희, Park Jihyepp. 641-642Whether Slow-Pull-Back or Standard Suction, Optimal Histologic Core Procurement Is Most Important Factor Rather than Blood Contamination or Cellularity in Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreatic Solid Tumor박세우pp. 643-645Proton Pump Inhibitor-Related Gastric Mucosal Changes김광하pp. 646-652
원문 보기